title: Civil society strategy for the compulsory   licensing of lopinavir/ritonavir:   the Brazilian case.
abstract: The flexibilities in the TRIPS Agreement (Trade Related Aspects of Intellectual Property) have been very useful in lowering the prices of antiretrovirals (ARVs) in Brazil. In this article, based on several presentations made at the conference, Marcela Fogaça Vieira et al describe recent developments in Brazil, including the granting of a compulsory licence for efavirenz.
authors.forename: Marcela Fogaça
authors.initials: MF
authors.lastname: Vieira
authors.forename: Renata
authors.initials: R
authors.lastname: Reis
authors.forename: Gabriela
authors.initials: G
authors.lastname: Chaves
mesh_terms: D001938:Brazil; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*
chemical_list: D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir